2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Polycystic Ovary Syndrome
9
Hyperandrogenism
4
Neoplasms
3
Inflammation
2
Heart Failure
2
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Skin Diseases
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Sarcoma
1
Retinitis
1
Renal Insufficiency, Chronic
1
Rare Diseases
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Obesity
1
Neutropenia
1
Migraine Disorders
1
Metabolic Syndrome
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Interventions
Doxorubicin
17
Echocardiography
14
Exercise
9
Cyclophosphamide
9
Trastuzumab
8
Dexrazoxane
8
Electrocardiography
7
Razoxane
6
Carvedilol
6
Vincristine
4
Radiotherapy
4
Filgrastim
4
Docetaxel
4
Methotrexate
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Cisplatin
3
Atorvastatin
3
salicylhydroxamic acid
2
sacubitril and valsartan sodium hydrate drug combination
2
empagliflozin
2
dapagliflozin
2
Tablets
2
Social Determinants of Health
2
Silymarin
2
Prednisone
2
Paclitaxel
2
Neoadjuvant Therapy
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cardiotoxicity
×
Spironolactone
×
Clear all
NCT06005259
2023-08-22
SPIROTOX
University of Sao Paulo
Phase 4
Unknown
264 enrolled